Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5750
+0.00150.26%
Pre-market: 0.59560.0206+3.58%06:38 EDT
Volume:7.07M
Turnover:3.92M
Market Cap:139.73M
PE:-0.77
High:0.5904
Open:0.5800
Low:0.5314
Close:0.5735
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:1.39
T/O Rate:3.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-13.44
PE(LYR):-0.32

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 03:00 Pm

Reuters
·
Jul 25

Outlook jumps 24% to $1.64 after FDA approves wet AMD treatment

TIPRANKS
·
Jul 25

Outlook Therapeutics Announces Lytenava FDA Approval for Treatment of Wet AMD

Reuters
·
Jul 25

US FDA Approves Outlook Therapeutics' Eye Disease Drug

Reuters
·
Jul 25

Outlook Therapeutics Inc: Anticipated 12 Years of Market Exclusivity Under Biologics Price Competition and Innovation Act

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics - Lytenava Expected to be Available to U.S. Patients Before Year-end

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics Announces Lytenava™ FDA Approval as the First and Only Fda-approved Ophthalmic Bevacizumab for the Treatment of Wet Amd

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics Inc trading halted, news pending

TIPRANKS
·
Jul 25

NASDAQ Trade Halt Halt News Pending at 01:34 Pm

Reuters
·
Jul 25

Outlook Therapeutics Grants CEO, CFO Options at $1.43 Per Share

Reuters
·
Jul 24

Outlook Therapeutics Registers 17.3 Million Shares for Resale

MT Newswires Live
·
Jul 18

Outlook Therapeutics Shareholders Approve Increase in Authorized Common Shares to 600 Million

Reuters
·
Jul 17

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)

TIPRANKS
·
Jun 30

Outlook Therapeutics Regains Nasdaq Compliance

MT Newswires Live
·
Jun 29

Outlook Therapeutics Regains NASDAQ Compliance After Shares Hold Above $1 Bid Threshold

Reuters
·
Jun 27

Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application

Dow Jones
·
Jun 16

BUZZ-Outlook Therapeutics rises after US FDA accepts to review eye disease treatment

Reuters
·
Jun 16

Outlook Therapeutics says FDA accepts resubmitted Lytentava BLA for wet AMD review

Reuters
·
Jun 16

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for Ons-5010/Lytenava™ (Bevacizumab-Vikg) as a Treatment for Wet Amd

THOMSON REUTERS
·
Jun 16